[Biosimilar Version of Trastuzumab]
Hetero, a globally renowned vertically integrated pharmaceutical organization announced today that its biologics arm Hetero Biopharma launched ‘Herti’ a biosimilar version of Trastuzumab in India market. “Herti” approved for the treatment of patients with HER-2 positive breast cancer.
Tocilizumab is a recombinant humanized anti-human interleukin 6 (IL-6) receptor monoclonal antibody of the immunoglobulin IgG1κ (gamma 1, kappa) subclass with a typical H2L2 polypeptide structure. Each light chain and heavy chain consists of 214 and 448 amino acids, respectively.
[Biosimilar Darbepoetin Alfa]
Launched in 2014, Derise is our first biosimilar and we are the second company in the world to launch the Biosimilar Darbepoetin Alfa, for treating anemia due to chronic kidney failure and chemotherapy induced anemia.
Our 2nd Biosimilar and the 1st Monoclonal AntiBody of Hetero Biopharma, Rilast was launched in 2015. It is today helping in the treatment of several conditions including: Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukaemia and Rheumatoid arthritis.
Launched in 2016, Bevaas is Hetero’s second monoclonal antibody and the third biosimilar product, that is offering major relief for conditions such as Metastatic Colorectal Cancer, Lung Cancer and Renal cancer.
Our recent offering, launched in 2017, Pamera is intended for the treatment of various types of autoimmune disorders like Rheumatoid arthritis (RA), Psoriatic Arthritis (PA) and Methotrexate Resistant Arthritis (MRA). As a drug, Adalimumab is the world’s largest selling product.